Observational study of contracts processing at 29 CTSA sites
- PMID: 23919362
- PMCID: PMC3740442
- DOI: 10.1111/cts.12073
Observational study of contracts processing at 29 CTSA sites
Erratum in
- Clin Transl Sci. 2014 Aug;7(4):348
Abstract
We measured contracts final negotiation (FN) and full execution (FE) times using shared definitions in a prospective observational study of management of contracts for clinical trials at 29 CTSA institutions. Median FN and FE times were reached in 39 and 91 days, respectively; mean times for FN and FE were 55 and 103 days, respectively. Individual site medians ranged from 3 to 116 days for FN and 34 to 197 days for FE. The use of master agreements (MAs) and previously negotiated terms (PNTs) was associated with significant reduction of FN times by a mean of 33 days (p < 0) and 22 days (p < 0.001), respectively. PNTs, but not MAs, were associated with significantly reduced FE time (22 days, p < 0.007). Gap analysis revealed a gap of 22 days between contracts negotiation and Institutional Review Board (IRB) review and intervals of 33 days (contracts) and 48 days (IRB review) during which the process steps were being conducted alone, suggesting a potential benefit with parallel processing. These baseline data support a plan to investigate root causes of prolonged study start-up time by examining causes of variation and outliers.
Keywords: CTSA Consortium; clinical research management; clinical trials; contracts; public private partnerships; virtual national laboratory.
© 2013 Wiley Periodicals, Inc.
References
-
- Schulman KA, Sells DM, Timble JW, Sugarman J, Dame LA, Weinfurt KP, Mark DB, Califf RM. A national survey of provisions in clinical‐trial agreements between medical schools and industry sponsors. N Engl J Med. 2002; 347:1335–1341. - PubMed
-
- Morrison BW. Industry Sponsored Trials at Academic Medical Centers: Goals and Requirements. https://www.ctsacentral.org/clinical‐research‐management‐workshop‐15. Accessed May 15, 2013.
-
- Dilts DM, Sandler AB. Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials. J Clin Oncol. 2006; 24: 4545–4552. - PubMed
-
- Dilts DM, Sandler AB, Baker M, Cheng SK, George SL, Karas KS, McGuire S, Menon GS, Reusch J, Sawyer D, et al. Processes to activate phase III clinical trials in a cooperative oncology group: the case of cancer and leukemia group B. J Clin Oncol. 2006; 24: 4553–4557. - PubMed
-
- Zerhouni E. Translational and clinical science–time for a new vision. N Engl J Med. 2005; 353: 1651–1653. - PubMed
Publication types
MeSH terms
Grants and funding
- UL1 TR000445/TR/NCATS NIH HHS/United States
- UL1 TR000128/TR/NCATS NIH HHS/United States
- UL1-TR000002/TR/NCATS NIH HHS/United States
- UL1-TR000064/TR/NCATS NIH HHS/United States
- UL1 TR000006/TR/NCATS NIH HHS/United States
- UL1-TR000003/TR/NCATS NIH HHS/United States
- UL1 TR000439/TR/NCATS NIH HHS/United States
- UL1-TR000424/TR/NCATS NIH HHS/United States
- UL1 TR000004/TR/NCATS NIH HHS/United States
- UL1 TR000457/TR/NCATS NIH HHS/United States
- UL1 TR000430/TR/NCATS NIH HHS/United States
- UL1-TR000427/TR/NCATS NIH HHS/United States
- UL1-TR000067/TR/NCATS NIH HHS/United States
- UL1 TR000090/TR/NCATS NIH HHS/United States
- UL1-TR000105/TR/NCATS NIH HHS/United States
- UL1 TR000150/TR/NCATS NIH HHS/United States
- UL1 TR000086/TR/NCATS NIH HHS/United States
- UL1 TR000427/TR/NCATS NIH HHS/United States
- UL1 TR000064/TR/NCATS NIH HHS/United States
- UL1-TR000371/TR/NCATS NIH HHS/United States
- UL1-TR-000004/TR/NCATS NIH HHS/United States
- UL1 TR000042/TR/NCATS NIH HHS/United States
- UL1-TR000086/TR/NCATS NIH HHS/United States
- UL1-TR000448/TR/NCATS NIH HHS/United States
- UL1 TR000093/TR/NCATS NIH HHS/United States
- UL1 TR000442/TR/NCATS NIH HHS/United States
- UL1-TR000090/TR/NCATS NIH HHS/United States
- UL1 TR001108/TR/NCATS NIH HHS/United States
- UL1-TR000150/TR/NCATS NIH HHS/United States
- UL-1-TR000128/TR/NCATS NIH HHS/United States
- UL1 TR000436/TR/NCATS NIH HHS/United States
- UL1-TR000109/TR/NCATS NIH HHS/United States
- UL1 TR000003/TR/NCATS NIH HHS/United States
- UL1-TR000439/TR/NCATS NIH HHS/United States
- UL1-TR000006/TR/NCATS NIH HHS/United States
- UL1 TR000135/TR/NCATS NIH HHS/United States
- U54 TR000123/TR/NCATS NIH HHS/United States
- UL1-TR000077/TR/NCATS NIH HHS/United States
- UL1-TR000142/TR/NCATS NIH HHS/United States
- UL1-TR000445/TR/NCATS NIH HHS/United States
- UL1-TR000457/TR/NCATS NIH HHS/United States
- UL1-TR000436/TR/NCATS NIH HHS/United States
- UL1 TR000424/TR/NCATS NIH HHS/United States
- UL1 TR000142/TR/NCATS NIH HHS/United States
- UL1 TR000067/TR/NCATS NIH HHS/United States
- UL1 TR001085/TR/NCATS NIH HHS/United States
- UL1 TR000448/TR/NCATS NIH HHS/United States
- UL1-TR000083/TR/NCATS NIH HHS/United States
- UL1 TR000002/TR/NCATS NIH HHS/United States
- UL1 TR000170/TR/NCATS NIH HHS/United States
- UL1 TR000083/TR/NCATS NIH HHS/United States
- UL1 TR000105/TR/NCATS NIH HHS/United States
- UL1-TR000170/TR/NCATS NIH HHS/United States
- UL1-TR000042/TR/NCATS NIH HHS/United States
- UL1-TR000442/TR/NCATS NIH HHS/United States
- UL1 TR000077/TR/NCATS NIH HHS/United States
- UL1 TR000109/TR/NCATS NIH HHS/United States
- UL1-TR000093/TR/NCATS NIH HHS/United States
- UL1-TR000430/TR/NCATS NIH HHS/United States
- UL1-TR000135/TR/NCATS NIH HHS/United States
- UL1 TR000371/TR/NCATS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
